Zymogenetics, Inc.

Steven D Bain

Virender M Labroo

James R Piggott

Methods and pharmaceutical compositions for reducing bone loss are disclosed. 3,4-diarylchromans and their pharmaceutically acceptable salts are formulated into medicaments for the treatment of bone loss due to osteoporosis or other conditions. An exemplary 3,4-diarylchroman is centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-[p-(beta-pyrrolidinoethoxy)phenyl]-7-me thoxychroman). Formulations include tablets and other forms suitable for oral administration and controlled-release subdermal implants.

Method for inhibiting bone loss using centchroman derivatives

Methods and pharmaceutical compositions for reducing bone loss are disclosed. 3,4-diarylchromans and their pharmaceutically acceptable salts are formulated into medicaments for the treatment of bone loss due to osteoporosis or other conditions. An exemplary 3,4-diarylchroman is centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-[p-(beta-pyrrolidinoethoxy)phenyl]-7-me thoxy-chroman). Formulations include tablets and other forms suitable for oral administration and controlled-release subdermal implants.

Growing community of inventors

Seattle, WA, United States of America

Steven D Bain